A new clinical trial exploring the efficacy of the Neuspera Sacral Neuromodulation (SNM) System for urinary urge incontinence is on the horizon. Set to commence under Neuspera Medical, Inc., the trial will assess the system through 30-minute stimulation sessions. This announcement is relevant for clinical professionals, regulatory specialists, and medical device quality teams.
Publication Date: November 26, 2025
What are the trial details?
The upcoming trial will focus specifically on urinary urge incontinence, a condition that affects millions worldwide and significantly impacts daily life. Sponsored by Neuspera Medical, Inc., the study involves a novel device designed for implantable sacral neuromodulation. Although recruitment has not yet begun, the planned research will provide crucial insight into the safety and performance of the device.
Participants will undergo 30-minute stimulation sessions, with investigators evaluating therapeutic outcomes. Any updates on recruitment timelines or initial results will be essential for stakeholders monitoring emerging medical technologies.
What is the Neuspera SNM system?
The Neuspera SNM system is a cutting-edge implantable device targeting sacral neuromodulation—the modulation of sacral nerve activity to manage the symptoms of urinary urge incontinence. Neuspera Medical states that this advanced system offers distinct advantages, including a compact, minimally invasive design.
As sacral neuromodulation therapies evolve, devices such as this could become critical tools for managing conditions that disrupt patient quality of life.
Who is affected?
This announcement is aimed at healthcare professionals, device regulators, and manufacturers involved in the development of advanced treatments for pelvic floor disorders. Patients struggling with urinary urge incontinence may also benefit indirectly as medical teams prepare to assess the device’s clinical relevance and viability.
For regulatory teams, the trial underscores the importance of emerging standards in device testing, safety assessments, and patient-centric innovations.
Frequently Asked Questions
1. What is urinary urge incontinence?
Urinary urge incontinence is a condition characterized by sudden, uncontrollable urges to urinate, often leading to leakage.
2. How does sacral neuromodulation work?
This therapy involves electrical stimulation of sacral nerves to restore bladder control.
3. When will the trial start recruiting?
According to the announcement, recruitment has not yet begun. Stakeholders should monitor updates on ClinicalTrials.gov.
4. Is Neuspera Medical known for SNM systems?
Yes, the company specializes in compact, innovative solutions for sacral neuromodulation.
Conclusion
Neuspera Medical’s upcoming trial presents a meaningful opportunity to explore advanced neuromodulation therapies for urinary urge incontinence. Professionals across clinical, regulatory, and quality sectors should continue monitoring this study for key updates and developments.
Disclaimer
This post is intended for informational purposes only and does not constitute legal advice. Consult regulatory documentation or professionals for specific guidance.
Further announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07247136?term=medical+device